Decoding the interaction between miR-19a and CBX7 focusing on the implications for tumor suppression in cancer therapy.
Arefeh Zabeti TouchaeiSogand VahidiAli Akbar SamadaniPublished in: Medical oncology (Northwood, London, England) (2023)
Cancer is a complex and multifaceted disease characterized by uncontrolled cell growth, genetic alterations, and disruption of normal cellular processes, leading to the formation of malignant tumors with potentially devastating consequences for patients. Molecular research is important in the diagnosis and treatment, one of the molecular mechanisms involved in various cancers is the fluctuation of gene expression. Non-coding RNAs, especially microRNAs, are involved in different stages of cancer. MicroRNAs are small RNA molecules that are naturally produced within cells and bind to the 3'-UTR of target mRNA, repressing gene expression by regulating translation. Overexpression of miR-19a has been reported in human malignancies. Upregulation of miR-19a as a member of the miR-17-92 cluster is key to tumor formation, cell proliferation, survival, invasion, metastasis, and drug resistance. Furthermore. bioinformatics and in vitro data reveal that the miR-19a-3p isoform binds to the 3'UTR of CBX7 and was identified as the miR-19a-3p target gene. CBX7 is known as a tumor suppressor. This review initially describes the regulation of mir-19a in multiple cancers. Accordingly, the roles of miR-19 in affecting its target gene expression CBX7 in carcinoma also be discussed.
Keyphrases
- cell proliferation
- gene expression
- long non coding rna
- long noncoding rna
- cell cycle
- dna methylation
- genome wide
- cancer therapy
- poor prognosis
- papillary thyroid
- end stage renal disease
- endothelial cells
- squamous cell carcinoma
- induced apoptosis
- ejection fraction
- chronic kidney disease
- drug delivery
- signaling pathway
- oxidative stress
- electronic health record
- single cell
- single molecule
- deep learning
- data analysis